Ultrasensitive immunoassays are becoming increasingly important when researchers need to detect proteins and biomarkers that exist at extremely low concentrations.
For Thermo Fisher Scientific, this opportunity fits into a much larger business covering laboratory equipment, reagents, diagnostics, genomics, bioproduction and research services. Its position is therefore different from specialist companies that focus almost entirely on ultra-sensitive biomarker detection.
The Technology Advantage: Where Thermo Fisher Stands
Thermo Fisher’s ProQuantum High-Sensitivity Immunoassays are designed to improve the detection of low-abundance proteins using antibody-based target recognition combined with qPCR signal amplification.
The platform can use only 2–5 µL of sample and offers a dynamic range of at least 5 orders of magnitude, according to Thermo Fisher.
Another practical advantage is that ProQuantum can operate on compatible real-time PCR instruments rather than requiring customers to purchase a completely new dedicated analyzer.
For laboratories that already have qPCR infrastructure, this can make adoption easier and potentially reduce additional equipment costs.
Understand your competitors, uncover untapped regions, identify investment opportunities, and get expert guidance personalized to your business, Download Sample: https://www.towardshealthcare.com/download-sample/5034
| ProQuantum feature | Reported specification |
|---|---|
| Sample requirement | 2–5 µL |
| Dynamic range | ≥5 logs |
| Typical workflow | 2 hours |
| Detection approach | Antibody + qPCR amplification |
| Dedicated instrument | Not required |
| Example IFN-γ sensitivity | <0.01 pg/mL |
| Example IL-17F sensitivity | <0.01 pg/mL |
These characteristics are particularly relevant to research involving neuroscience, immunology, oncology, inflammation and cell therapy.
Where the Commercial Opportunity Is Strongest
The most interesting opportunity is not simply selling another immunoassay kit.
The larger opportunity is helping researchers measure biomarkers that can be difficult to detect with conventional assays.
In neuroscience, for example, very low concentrations of biomarkers can be important when studying neurodegenerative diseases. In oncology and immunology, researchers may need to track cytokines, immune-response markers and treatment-related changes.
This creates demand for assays that use less sample while delivering high sensitivity and reproducible results.
For Thermo Fisher, the advantage is that these assays can potentially sit alongside its existing PCR, sequencing, antibody, cell-analysis and laboratory workflows.
That gives the company multiple opportunities to sell products to the same pharmaceutical, biotechnology and academic customers.
Thermo Fisher Has the Financial Scale to Support Expansion
Thermo Fisher generated approximately $44.6 billion in revenue in 2025, compared with $42.9 billion in 2024.
The company spent approximately $1.4 billion on research and development in 2025, demonstrating the financial capacity to continue developing new technologies and expanding its portfolio.
Importantly, Thermo Fisher does not separately report revenue from ProQuantum. Therefore, its contribution cannot be reliably calculated from public financial statements.
| Financial indicator | 2024 | 2025 |
| Revenue | $42.9B | $44.6B |
| R&D | $1.39B | $1.40B |
| Revenue growth | – | 4% |
| ProQuantum revenue | Not separately reported | Not separately reported |
The broader financial picture is important because Thermo Fisher can invest in technologies that may initially generate relatively small revenue but become strategically valuable as adoption increases.
Thermo Fisher vs. Specialist Players
The competitive picture becomes clearer when Thermo Fisher is compared with Quanterix.
Quanterix has built its business around ultrasensitive biomarker detection, particularly through its Simoa platform. Its specialization gives it a strong position in applications where extremely sensitive protein measurement is the primary requirement.
Thermo Fisher takes a broader approach.
Its advantage is the ability to combine immunoassays with PCR, genomics, cell analysis, laboratory instruments and bioproduction technologies.
| Company | Main strength | Strategic advantage |
| Thermo Fisher | Broad life-science ecosystem | Large customer base + multiple technologies |
| Quanterix | Ultrasensitive biomarker detection | Specialist Simoa platform |
| Bio-Techne | Protein analysis & reagents | Strong research reagent portfolio |
| Bio-Rad | Immunoassays & digital PCR | Integrated analytical technologies |
The key question for customers is therefore not simply “Which company has the lowest detection limit?”
It is also about assay availability, reproducibility, sample volume, workflow compatibility, throughput, software, instrument requirements and cost per test.
Why Neuroscience Could Be Particularly Important
Neuroscience is one of the areas where ultrasensitive biomarker testing could become increasingly valuable.
Researchers are studying biomarkers associated with Alzheimer’s disease, Parkinson’s disease and other neurological disorders, while pharmaceutical companies need better tools for patient selection, disease monitoring and clinical-trial research.
A platform that can detect extremely low concentrations from limited samples may therefore become useful across several stages of drug development.
For Thermo Fisher, this could create additional demand from pharmaceutical companies running biomarker-driven clinical trials.
However, adoption will depend on whether researchers can demonstrate that these measurements improve clinical or research decisions rather than simply providing greater analytical sensitivity.
Investment: Where Thermo Fisher Is Putting Its Money
Thermo Fisher is investing well beyond individual immunoassay products.
In 2025, the company announced plans for an additional $2 billion investment in U.S. operations over four years, including approximately $1.5 billion in capital expenditure and $500 million in R&D.
The company also continues to use acquisitions to expand its capabilities.
Its announced acquisition of Clario for approximately $8.9 billion was aimed at strengthening clinical-trial endpoint data and digital capabilities.
This strategy matters for ultrasensitive immunoassays because the future of biomarker research is becoming increasingly connected with clinical-trial data, precision medicine and digital patient information.
What Could Limit Growth?
The biggest challenge is competition from specialist platforms.
Quanterix, Bio-Techne, Bio-Rad and other research technology companies are competing for the same pharmaceutical and academic customers.
Another issue is that high analytical sensitivity does not automatically translate into clinical value.
Researchers still need strong specificity, reproducibility, validated assays, standardized workflows and clinically meaningful biomarkers.
Cost is another consideration. Laboratories may be reluctant to change established workflows unless the additional sensitivity provides a clear research or clinical benefit.
What Should Leaders Evaluate Before Investing?
For leaders considering investment in Thermo Fisher’s ultrasensitive immunoassay opportunity, four areas deserve close attention.
1. Technology performance
Look at detection limits, precision, specificity, dynamic range and reproducibility rather than relying only on headline sensitivity.
2. Customer adoption
Track pharmaceutical partnerships, clinical-trial use, published research, assay-menu expansion and repeat consumables demand.
3. Competitive differentiation
Compare ProQuantum directly with Simoa and other technologies based on sample volume, workflow, throughput, instrument requirements and total cost.
4. Commercial scalability
Assess whether Thermo Fisher can turn ultrasensitive assays into recurring reagent and consumables revenue through its existing global customer network.
The strongest investment opportunity would be where higher sensitivity produces a measurable improvement in drug discovery, biomarker research or clinical development.
Thermo Fisher’s strength in ultrasensitive immunoassays is not based solely on the ProQuantum technology.
Its bigger advantage is the ability to connect high-sensitivity protein measurement with PCR, genomics, cell analysis, laboratory equipment and pharmaceutical research workflows.
With approximately $44.6 billion in 2025 revenue and $1.4 billion in R&D spending, the company has significant resources to expand this technology category.
The main opportunity is the growing need for low-level biomarker detection, particularly in neuroscience, oncology, immunology and precision medicine.
For investors and healthcare leaders, the most important signals to monitor are assay adoption, new biomarker panels, pharmaceutical partnerships, clinical-trial applications, recurring consumables revenue and Thermo Fisher’s ability to differentiate ProQuantum from specialist platforms such as Quanterix Simoa.
Quick Links
Don’t miss out personalized dashboard built around your niche; with the exact data and insights you need. Request for a demo: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research & Consulting which is a global healthcare market research and consulting firm dedicated to helping businesses make informed decisions through reliable market intelligence and strategic insights. We serve pharmaceutical, biotechnology, medical device, AI in healthcare, cell and gene therapy, digital health, and life sciences organizations with in-depth market research, custom consulting, competitive analysis, and growth forecasts. Our team combines industry expertise with rigorous research to deliver clear, actionable insights that support market expansion, product strategy, investment decisions, and long-term business growth. From emerging innovations to established healthcare markets, we help organizations understand where the industry is today and where it’s headed tomorrow.
Connect with us for more enquiry at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium